Chemicals and drugs often cause health problems by altering gene expression and other cell activity, and research on these processes -- called toxicogenomic research -- could eventually lead to more-sensitive toxicity tests that can supplement current tests, the report says. Toxicogenomic tests can also pinpoint individuals with genetic vulnerabilities and help them avoid chemicals or medications that might make them ill.
A major, coordinated effort approaching the scale of the Human Genome Project is needed both to develop these technologies fully and to address the ethical challenges they pose, such as protecting the confidentiality of individuals' genetic information, the report says. As part of this endeavor, which could be called a "human toxicogenomics initiative," a new database is needed to consolidate the massive amounts of data currently being generated by toxicogenomic studies.
"We have just begun to tap the potential for toxicogenomic technologies to improve risk assessment," said David Christiani, chair of the committee that wrote the report, and professor of occupational medicine and epidemiology at the Harvard School of Public Health. "To harvest public health benefits requires both greater investment in research and coordinated leadership."
Toxic substances and drugs can potentially disrupt gene processes within cells, thus disturbing the cells' healthy functioning. In addition, an individual's genetic variations can leave him or her particularly susceptible to the effects of chemicals or side effects of medications. For example, studies have shown that certain inherited gene variations may make some people more prone to symptoms such as nausea and impaired muscle function when exposed to a common pesticide, the report notes.
Using new toxicogenomic technologies, researchers can identify toxic processes as they unfold at an early, molecular stage, long before symptoms appear. This knowledge will support the development of tests that can more accurately predict whether a chemical will be hazardous, and at what dose. The tests' sensitivity also could lead to better prediction and prevention of damage to fetuses at critical stages of development. Finally, toxicogenomic studies can inform individuals about their particular genetic vulnerabilities.
Given the potential of toxicogenomics to reduce and prevent health risks, regulatory agencies should expand their research and enhance efforts to use these methods to aid risk assessments, the report says. It also calls on the National Institute of Environmental Health Sciences and other stakeholders in government, academia, and industry to explore the feasibility of implementing a concerted human toxicogenomics initiative.
A crucial part of this effort will be the creation of a single public database to collect toxicogenomic data and integrate it with data on health effects generated by traditional toxicology studies, the report says. Such a database will let scientists see connections between activity at a molecular level and the symptoms that result, and decipher how multiple genetic reactions at the cellular level can combine to cause adverse outcomes. New studies will also be needed to generate data on the genomic effects of chemicals for which traditional toxicity data already exist. And a national "biorepository" for physical samples -- human blood and tissue, for example -- will be useful for future toxicogenomic studies. Every effort should be made to use samples already being collected for other research, the report urges.
The generation of data from such studies, and toxicogenomic research in general, raises a host of social, legal, and ethical questions that the new initiative needs to address -- including protecting the privacy of genetic and health data, the report says. Individuals might decide against genetic testing if there is a danger that health insurers or employers could access their information and use it to deny them insurance or work. Safeguarding the privacy of this data will be increasingly challenging as the use of electronic medical records grows.
Improved legislation is needed to protect the privacy, confidentiality, and security of health information anywhere it is collected, stored, and transmitted -- not just at organizations already subject to privacy rules under the Health Insurance Portability and Accountability Act. The decision to learn about one's genetic vulnerabilities should rest with the individual, the report says. And except in rare circumstances, people who choose to get tested to learn about their particular genetic susceptibilities to a workplace chemical should be allowed to decide for themselves whether to accept the risks involved in employment.
Sara Frueh | EurekAlert!
Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute
Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy